| | For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler. |
| 265 | Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy; |
| | LU Authorization Period: Indefinite |
| 266 | Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;. |
| | LU Authorization Period: Indefinite |
| 267 | Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities; |
| | LU Authorization Period: Indefinite |
| 268 | Patients who have previously used nebulizer therapy within the last 12 month period. |
| | LU Authorization Period: Indefinite |
